Scutellarin alleviates interstitial fibrosis and cardiac dysfunction of infarct rats by inhibiting TGFβ1 expression and activation of p38-MAPK and ERK1/2

British Journal of Pharmacology

Volumn 162, Issue 3, 2011, Pages 688-700

  Pan, Zhenwei ^a,b   Zhao, Weiming ^a   Zhang, Xiangying ^a   Wang, Bing ^a   Wang, Jinghao ^a   Sun, Xuelin ^a   Liu, Xuantong ^a   Feng, Shuya ^a   Yang, Baofeng ^a,b   Lu, Yanjie ^a,b  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b Department of Pharmacology and Bio pharmaceutical   (China)

Author keywords

cardiac infarction; ERK1 2; fibrosis; p38 MAPK; scutellarin; TGF 1

Indexed keywords

ANGIOTENSIN II; FIBRONECTIN; FIBRONECTIN 1; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE P38; SCUTELLARIN; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FIBROBLAST; HEART FUNCTION; HEART HEMODYNAMICS; HEART INFARCTION; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; APIGENIN; COLLAGEN; CYTOKINES; DRUGS, CHINESE HERBAL; ECHOCARDIOGRAPHY; ERIGERON; FIBROSIS; GLUCURONIC ACIDS; HEART FAILURE; HEMODYNAMICS; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MYOCARDIAL INFARCTION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHYTOTHERAPY; RATS; RATS, WISTAR; TRANSFORMING GROWTH FACTOR BETA1; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 78651420043     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01070.x     Document Type: Article

References (43)

1. Boluyt MO, ONeill L, Meredith AL, Bing OH, Brooks WW, Conrad CH, et al. (1994). Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Marked upregulation of genes encoding extracellular matrix components. Circ Res 75: 23-32.
2. Bujak M, Frangogiannis NG, (2007). The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc Res 74: 184-195.
3. Chan JY, Tan BK, Lee SC, (2009). Scutellarin sensitizes drug-evoked colon cancer cell apoptosis through enhanced caspase-6 activation. Anticancer Res 29: 3043-3047.
4. Chen J, Mehta JL, (2006). Angiotensin II-mediated oxidative stress and procollagen-1 expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 291: H1738-H1745.
5. van Deel ED, Lu Z, Xu X, Zhu G, Hu X, Oury TD, et al. (2008). Extracellular superoxide dismutase protects the heart against oxidative stress and hypertrophy after myocardial infarction. Free Radic Biol Med 44: 1305-1313.
6. Dorn GW, II (2009). Novel pharmacotherapies to abrogate postinfarction ventricular remodeling. Nat Rev Cardiol 6: 283-291.
7. Fan WJ, van Vuuren D, Genade S, Lochner A, (2010). Kinases and phosphatases in ischaemic preconditioning: a re-evaluation. Basic Res Cardiol 105: 495-511.
8. Gao X, He X, Luo B, Peng L, Lin J, Zuo Z, (2009). Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur J Pharmacol 606: 115-120.
9. Hein S, Arnon E, Kostin S, Schonburg M, Elsasser A, Polyakova V, et al. (2003). Progression from compensated hypertrophy to failure in the pressure-overloaded human heart: structural deterioration and compensatory mechanisms. Circulation 107: 984-991.
10. Jia JH, Chen KP, Chen SX, Liu KZ, Fan TL, Chen YC, (2008). Breviscapine, a traditional Chinese medicine, alleviates myocardial ischaemia reperfusion injury in diabetic rats. Acta Cardiol 63: 757-762.
11. Kobayashi H, Minatoguchi S, Yasuda S, Bao N, Kawamura I, Iwasa M, et al. (2008). Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 79: 611-620.
12. Kompa AR, See F, Lewis DA, Adrahtas A, Cantwell DM, Wang BH, et al. (2008). Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction. J Pharmacol Exp Ther 325: 741-750.
13. Kurrelmeyer K, Kalra D, Bozkurt B, Wang F, Dibbs Z, Seta Y, et al. (1998). Cardiac remodeling as a consequence and cause of progressive heart failure. Clin Cardiol 21 (Suppl. 1): I14-I19.
14. Li XL, Li YQ, Yan WM, Li HY, Xu H, Zheng XX, et al. (2004). A study of the cardioprotective effect of breviscapine during hypoxia of cardiomyocytes. Planta Med 70: 1039-1044.
15. Lin JF, Lin SM, Chih CL, Nien MW, Su HH, Hu BR, et al. (2008). Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci 83: 313-317.
16. Lin LL, Liu AJ, Liu JG, Yu XH, Qin LP, Su DF, (2007). Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 50: 327-332.
17. Muslin AJ, (2008). MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets. Clin Sci (Lond) 115: 203-218.
18. Okada H, Takemura G, Kosai K, Li Y, Takahashi T, Esaki M, et al. (2005). Postinfarction gene therapy against transforming growth factor-beta signal modulates infarct tissue dynamics and attenuates left ventricular remodeling and heart failure. Circulation 111: 2430-2437.
19. Olson ER, Naugle JE, Zhang X, Bomser JA, Meszaros JG, (2005). Inhibition of cardiac fibroblast proliferation and myofibroblast differentiation by resveratrol. Am J Physiol Heart Circ Physiol 288: H1131-H1138.
20. Olson ER, Shamhart PE, Naugle JE, Meszaros JG, (2008). Angiotensin II-induced extracellular signal-regulated kinase 1/2 activation is mediated by protein kinase Cdelta and intracellular calcium in adult rat cardiac fibroblasts. Hypertension 51: 704-711.
21. Pan Z, Feng T, Shan L, Cai B, Chu W, Niu H, et al. (2008). Scutellarin-induced endothelium-independent relaxation in rat aorta. Phytother Res 22: 1428-1433.
22. 2+-mediated calcineurin and CaMKII signaling pathways. Naunyn Schmiedebergs Arch Pharmacol 381: 137-145.
23. Pfeffer MA, (1995). Left ventricular remodeling after acute myocardial infarction. Annu Rev Med 46: 455-466.
24. Pfeffer MA, Braunwald E, (1990). Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications. Circulation 81: 1161-1172.
25. Ren J, Zhang S, Kovacs A, Wang Y, Muslin AJ, (2005). Role of p38alpha MAPK in cardiac apoptosis and remodeling after myocardial infarction. J Mol Cell Cardiol 38: 617-623.
26. Schorb W, Conrad KM, Singer HA, Dostal DE, Baker KM, (1995). Angiotensin II is a potent stimulator of MAP-kinase activity in neonatal rat cardiac fibroblasts. J Mol Cell Cardiol 27: 1151-1160.
27. See F, Thomas W, Way K, Tzanidis A, Kompa A, Lewis D, et al. (2004). p38 mitogen-activated protein kinase inhibition improves cardiac function and attenuates left ventricular remodeling following myocardial infarction in the rat. J Am Coll Cardiol 44: 1679-1689.
28. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, et al. (1998). Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res 38: 116-124.
29. Stockand JD, Meszaros JG, (2003). Aldosterone stimulates proliferation of cardiac fibroblasts by activating Ki-RasA and MAPK1/2 signaling. Am J Physiol Heart Circ Physiol 284: H176-H184.
30. Sutton MG, Sharpe N, (2000). Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 101: 2981-2988.
31. Takenaka H, Horiba M, Ishiguro H, Sumida A, Hojo M, Usui A, et al. (2009). Midkine prevents ventricular remodeling and improves long-term survival after myocardial infarction. Am J Physiol Heart Circ Physiol 296: H462-H469.
32. Tan ZH, Yu LH, Wei HL, Liu GT, (2010). Scutellarin protects against lipopolysaccharide-induced acute lung injury via inhibition of NF-kappaB activation in mice. J Asian Nat Prod Res 12: 175-184.
33. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, et al. (2008). MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456: 980-984.
34. Vanhoutte D, Schellings M, Pinto Y, Heymans S, (2006). Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window. Cardiovasc Res 69: 604-613.
35. Wang LX, Zeng JP, Wei XB, Wang FW, Liu ZP, Zhang XM, (2007). Effects of scutellarin on apoptosis induced by cobalt chloride in PC12 cells. Chin J Physiol 50: 301-307.
36. Weber KT, (1997). Extracellular matrix remodeling in heart failure: a role for de novo angiotensin II generation. Circulation 96: 4065-4082.
37. White HD, Braunwald E, (1998). Applying the open artery theory: use of predictive survival markers. Eur Heart J 19: 1132-1139.
38. Wu M, Han M, Li J, Xu X, Li T, Que L, et al. (2009). 17beta-estradiol inhibits angiotensin II-induced cardiac myofibroblast differentiation. Eur J Pharmacol 616: 155-159.
39. Yan L, Huang H, Tang QZ, Zhu LH, Wang L, Liu C, et al. (2010). Breviscapine protects against cardiac hypertrophy through blocking PKC-alpha-dependent signaling. J Cell Biochem 109: 1158-1171.
40. Yang B, Lin H, Xiao J, Lu Y, Luo X, Li B, et al. (2007). The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13: 486-491.
41. Yang L, Zou XJ, Gao X, Chen H, Luo JL, Wang ZH, et al. (2009). Sodium tanshinone IIA sulfonate attenuates angiotensin II-induced collagen type I expression in cardiac fibroblasts in vitro. Exp Mol Med 41: 508-516.
42. Yeh CC, Li H, Malhotra D, Turcato S, Nicholas S, Tu R, et al. (2010). Distinctive ERK and p38 signaling in remote and infarcted myocardium during post-MI remodeling in the mouse. J Cell Biochem 109: 1185-1191.
43. Yousef ZR, Redwood SR, Marber MS, (2000). Postinfarction left ventricular remodelling: where are the theories and trials leading us? Heart 83: 76-80.